Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessment on the Deep Remission Rate and Its Influencing Factors of Individualized Ustekinumab Therapy in Patients With Crohn's Disease
Sponsor: Second Affiliated Hospital of Wenzhou Medical University
Summary
In alignment with the STRIDE-II consensus, the therapeutic goal for Crohn's disease (CD) has shifted towards "deep remission," which necessitates both mucosal and transmural healing. Recognizing the limitations of relying solely on endoscopic evaluation, this study aims to comprehensively assess the week-44 deep remission status in CD patients undergoing ustekinumab (UST) therapy. By systematically investigating baseline clinical, serological, and sonographic parameters, this research seeks to identify key predictive factors for deep remission, thereby providing robust clinical evidence to guide proactive and personalized UST optimization strategies.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
OBSERVATIONAL
Enrollment
156
Start Date
2021-01-01
Completion Date
2026-01-20
Last Updated
2026-05-20
Healthy Volunteers
No
Conditions
Locations (1)
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China